Recently, the significant therapeutic effect of SRI31215, a novel small molecule inhibitor of pro-HGF activation (inhibitor of hepsin, matriptase and HGF activator: similar function with HAIs), has been reported in MET-amplified non-small cell lung and gastric cancer cells [30,31,32]. This evidence concerns the gene MET and gastric cancer.